Latest external collaboration on country level. Dive into details by clicking on the dots.
Dive into the research topics where Luciana Armaganijan is active.
Featured researches published by Luciana Armaganijan.
Circulation-arrhythmia and Electrophysiology | 2009
Luigi Di Biase; Luis C. Sáenz; David Burkhardt; Miguel Vacca; Claude S. Elayi; Conor D. Barrett; Rodney Horton; Alan Siu; Tamer S. Fahmy; Dimpi Patel; Luciana Armaganijan; Chia Tung Wu; Sonne Kai; Ching Keong Ching; Karen Phillips; Robert A. Schweikert; Jennifer E. Cummings; Mauricio Arruda; Walid Saliba; Milan Dodig; Andrea Natale
Background—Left atrioesophageal fistula is a rare but devastating complication that may occur after catheter ablation of atrial fibrillation. We used capsule endoscopy to assess esophageal injury after catheter ablation for atrial fibrillation in a population randomized to undergo general anesthesia or conscious sedation. Methods and Results—Fifty patients undergoing atrial fibrillation ablation for paroxysmal symptomatic atrial fibrillation refractory to antiarrhythmic drugs were enrolled and randomized, including those undergoing the procedure under general anesthesia (25 patients, group 1) and those receiving conscious sedation with fentanyl or midazolam (25 patients, group 2). All patients underwent esophageal temperature monitoring during the procedure. The day after ablation, all patients had capsule endoscopy to assess the presence of endoluminal tissue damage of the esophagus. We observed esophageal tissue damage in 12 (48%) patients of group 1 and 1 esophageal tissue damage in a single patient (4%) of group 2 (P<0.001). The maximal esophageal temperature was significantly higher in patients undergoing general anesthesia (group 1) versus patients undergoing conscious sedation (group 2) (40.6±1°C versus 39.6±0.8°C; P< 0.003). The time to peak temperature was 9±7 seconds in group 1 and 21±9 seconds in group 2, and this difference was statistically significant (P<0.001). No complication occurred during or after the administration of the pill cam or during the procedures. All esophageal lesions normalized at the 2-month repeat endoscopic examination. Conclusion—The use of general anesthesia increases the risk of esophageal damage detected by capsule endoscopy.
Circulation | 2012
Christopher B. Granger; Luciana Armaganijan
The incidence of atrial fibrillation (AF) appears to be increasing, even after adjustment for aging of the population.1 One in 4 people is projected to develop AF in his or her lifetime.2 Patients with AF have a 5-fold increased risk of stroke, and it is estimated that 15% to 20% of all strokes are attributable to AF. Moreover, death and disability from stroke complicating AF are particularly high.3 Thus, stroke related to AF is a substantial and growing public health burden. Response by Ansell on p 164 Warfarin results in a two-thirds reduction in stroke on the basis of a meta-analysis of the randomized controlled trials4 (Figure). However, warfarin is grossly underused. In a relatively healthy insured population, ≈55% of eligible patients with AF received warfarin, and the rates dropped off substantially in the elderly, who have the greatest need.5 This low proportion of use and even greater underuse in higher-risk patients have been consistent findings across a number of US and European registries.6–8 In addition, not only is warfarin underused, but when it is used, it is used suboptimally.5 An inception cohort of elderly patients started on warfarin found that 28% of patients had discontinued warfarin by 1 year.9 Rates of major bleeding were very high, at >20% for patients with CHADS2 (an acronym for congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke or transient ischemic attack) score ≥4, during the first year, illustrating the vulnerability of patients on warfarin during initiation. International normalized ratios (INRs) were in the target range of 2.0 to 3.0 only 58% of the time. Reasons for underuse of warfarin and inability to consistently achieve target INR, at least in part, relate to pharmacological properties of the drug, including …
Heart Rhythm | 2012
Elizabeth S. Kaufman; Carsten W. Israel; Girish M. Nair; Luciana Armaganijan; Syamkumar Divakaramenon; Georges H. Mairesse; Axel Brandes; Eugene Crystal; Otto Costantini; Roopinder K. Sandhu; Ratika Parkash; Stuart J. Connolly; Stefan H. Hohnloser; Jeff S. Healey
BACKGROUND Pacemakers can automatically identify and catalog atrial high-rate episodes (AHREs). While most AHREs represent true atrial tachyarrhythmia/atrial fibrillation (AT/AF), a review of stored electrograms suggests that a substantial proportion do not. As AHREs may lead to the initiation of oral anticoagulation, it is crucial to understand the relationship between AHREs and true AT/AF. OBJECTIVE To compare the positive predictive value of AHREs for electrogram-confirmed AT/AF for various atrial rates and episode durations. METHODS By using data from 2580 patients who participated in the ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the AF Reduction atrial pacing Trial, all AHREs >6 minutes and >190 beats/min with available electrograms were reviewed to determine whether they represented true AT/AF. The positive predictive value of these AHREs was assessed for episode durations of 6 minutes, 30 minutes, 6 hours, and 24 hours at atrial rates of 190 and 250 beats/min. RESULTS Of 5769 AHREs >6 minutes and >190 beats/min, 82.7% were true AT/AF and 17.3% were false positives (predominantly due to repetitive non-re-entrant ventriculoatrial synchrony). False positives dropped to 6.8%, 3.3%, and 1.8% when the threshold duration was increased to 30 minutes, 6 hours, and 24 hours, respectively. Increasing the threshold heart rate to 250 beats/min added little to the positive predictive value when longer threshold durations were used. CONCLUSIONS By using a cutoff of >6 minutes and >190 beats/min, the rate of false-positive AHREs is 17.3%, making physician review of electrograms essential. For AHREs lasting >6 hours, the rate of false positives is 3.3%, making physician review less crucial.
Pacing and Clinical Electrophysiology | 2012
Luciana Armaganijan; William D. Toff; Jens Cosedis Nielsen; Henning Rud Andersen; Stuart J. Connolly; Kenneth A. Ellenbogen; Jeff S. Healey
Background: Patients over the age of 75 represent more than half the recipients of permanent pacemakers. It is not known if they have a different risk of complications than younger patients.
Journal of Cardiovascular Electrophysiology | 2008
Jennifer E. Cummings; Conor D. Barrett; Kenneth N. Litwak; Luigi Di Biase; Punam Chowdhury; Seil Oh; Chi Keong Ching; Walid Saliba; Robert A. Schweikert; J. David Burkhardt; Shari De Marco; Luciana Armaganijan; Andrea Natale
Introduction: Evaluation of luminal temperature during left atrial ablation is used clinically; however, luminal temperature does not necessarily reflect temperature within the esophageal wall and poses a risk of atrioesophageal fistula. This animal study evaluates luminal esophageal temperature and its relation to the temperature of the external esophageal tissue during left atrial lesions using the 8 mm solid tip and the open irrigated tip catheters (OIC).
Jacc-cardiovascular Interventions | 2015
Luciana Armaganijan; Rodolfo Staico; Dalmo Antonio Ribeiro Moreira; Renato D. Lopes; Paulo T.J. Medeiros; Ricardo Garbe Habib; Jônatas Melo Neto; Marcelo Katz; Dikran Armaganijan; Amanda Sousa; Felix Mahfoud; Alexandre Abizaid
OBJECTIVES This study aimed to assess 6-month outcomes in patients with implantable cardioverter-defibrillators (ICDs) undergoing renal sympathetic denervation (RSD) for refractory ventricular arrhythmias (VAs). BACKGROUND ICDs are generally indicated for patients at high risk of malignant VAs. Sympathetic hyperactivity plays a critical role in the development, maintenance, and aggravation of VAs. METHODS A total of 10 patients with refractory VA underwent RSD. Underlying conditions were Chagas disease (n = 6), nonischemic dilated cardiomyopathy (n = 2), and ischemic cardiomyopathy (n = 2). Information on the number of ventricular tachycardia (VT)/ventricular fibrillation (VF) episodes and device therapies (antitachycardia pacing/shocks) in the previous 6 months as well as 1 and 6 months post-treatment was obtained from ICD interrogation. RESULTS The median number of VT/VF episodes/antitachycardia pacing/shocks 6 months before RSD was 28.5 (range 1 to 106)/20.5 (range 0 to 52)/8 (range 0 to 88), respectively, and was reduced to 1 (range 0 to 17)/0 (range 0 to 7)/0 (range 0 to 3) at 1 month and 0 (range 0 to 9)/0 (range 0 to 7)/0 (range 0 to 3) at 6 months afterward, respectively. There were no major procedure-related complications. Two patients experienced sustained VT within the first week; in both cases, no further episodes occurred during follow-up. Two patients were nonresponders: 1 with persistent idioventricular rhythm and 1 with multiple renal arteries and incomplete ablation. Three patients died during follow-up. None of the deaths was attributed to VA. CONCLUSIONS In patients with ICDs and refractory VAs, RSD was associated with reduced arrhythmic burden with no procedure-related complications. Randomized controlled trials investigating RSD for treatment of refractory VAs in patients with increased sympathetic activity are needed.
Clinics | 2011
Luciana Armaganijan; Renato D. Lopes; Jeff S. Healey; Jonathan P. Piccini; Girish M. Nair; Carlos A. Morillo
OBJECTIVES: N-3 polyunsaturated fatty acids have been proposed as a novel treatment for preventing postoperative atrial fibrillation due to their potential anti-inflammatory and anti-arrhythmic effects. However, randomized studies have yielded conflicting results. The objective of this study is to review randomized trials of N-3 polyunsaturated fatty acid use for postoperative atrial fibrillation. METHODS: Using the CENTRAL, PUBMED, EMBASE, and LILACS databases, a literature search was conducted to identify all of the studies in human subjects that reported the effects of N-3 polyunsaturated fatty acids on the prevention of postoperative atrial fibrillation in cardiac surgery patients. The final search was performed on January 30, 2011. There was no language restriction, and the search strategy only involved terms for N-3 polyunsaturated fatty acids (or fish oil), atrial fibrillation, and cardiac surgery. To be included, the studies had to be randomized (open or blinded), and the enrolled patients had to be ≥18 years of age. RESULTS: Four randomized studies (three double-blind, one open-label) that enrolled 538 patients were identified. The patients were predominantly male, the mean age was 62.3 years, and most of the patients exhibited a normal left atrial size and ejection fraction. N-3 polyunsaturated fatty acid use was not associated with a reduction in postoperative atrial fibrillation. Similar results were observed when the open-label study was excluded. CONCLUSIONS: There is insufficient evidence to suggest that treatment with N-3 polyunsaturated fatty acids reduces postoperative atrial fibrillation. Therefore, their routine use in patients undergoing cardiac surgery is not recommended.
Cardiovascular Psychiatry and Neurology | 2013
Dimpi Patel; Nathaniel D. Mc Conkey; Ryann Sohaney; Ashley Mc Neil; Andy Jedrzejczyk; Luciana Armaganijan
Atrial fibrillation (AF) is the most commonly seen arrhythmia in clinical practice. At present, few studies have been conducted centering on depression and anxiety in AF patients. Our aim in this systematic review is to use the relevant literature to (1) describe the prevalence of depression and anxiety in AF patients, (2) assess the impact that depression and anxiety have on illness perception in patients with AF, (3) provide evidence to support a hypothetical connection between the pathophysiology of AF and depression and anxiety, (4) evaluate the benefit of treatment of AF on depression and anxiety, and (5) give insight on medically managing a patient with AF and concomitant depression and anxiety.
Europace | 2013
V. Expósito; Juan C. Guzman; M. Orava; Luciana Armaganijan; Carlos A. Morillo
AIMS The Calgary Syncope Symptom Score (CSSS) has been validated as a simple point score of historical features with high sensitivity and specificity for the diagnosis of vasovagal syncope (VVS) in younger populations without evidence of structural heart disease. Our purpose was to evaluate the performance of the CSSS in an elderly population with suspected VVS. METHODS AND RESULTS Hundred and eighty patients of ≥60 years of age (mean 73.4 ± 7.8) with suspected clinical diagnosis of VVS were studied. The CSSS (VVS score ≥-2) was calculated in all patients prior to undergoing head-up tilt test (HUT). A standardized HUT protocol with active nitroglycerin phase was used to reproduce syncopal symptoms as gold standard for diagnosis of VVS. Hundred and forty patients had positive HUT response. Eighty-three patients (42.3%) had CSSS ≥-2 suggesting a diagnosis of VVS. The Calgary Syncope Symptom Score sensitivity was 0.51 [95% confidence interval (CI) 0.42-0.59] and specificity 0.73 (95% CI 0.52-0.85) with positive predictive value and negative predictive value of 0.87 (95% CI 0.77-0.93) and 0.30 (95% CI 0.21-0.40), respectively. One hundred (55.6%) patients had previous history of mild cardiovascular disease documented during assessment prior to HUT. In this population sensitivity and specificity was markedly reduced: 0.13 (95% CI 0.05-0.29) and 0.70 (95% CI 0.57-0.80), respectively. CONCLUSION The CSSS has a lower sensitivity and specificity in an elderly population presenting with syncope compared to previously validated data in young adults, particularly in elderly patients with previous history of mild cardiovascular disease. A modified CSSS may be needed to improve specificity and sensitivity in this population.
Arquivos Brasileiros De Cardiologia | 2014
Luciana Armaganijan; Rodolfo Staico; Aline Moraes; Alexandre Abizaid; Dalmo Antonio Ribeiro Moreira; Celso Amodeo; Márcio Gonçalves de Sousa; Flávio A. O Borelli; Dikran Armaganijan; J. Eduardo Sousa; Amanda Sousa
Background Systemic hypertension is an important public health problem and a significant cause of cardiovascular mortality. Its high prevalence and the low rates of blood pressure control have resulted in the search for alternative therapeutic strategies. Percutaneous renal sympathetic denervation emerged as a perspective in the treatment of patients with resistant hypertension. Objective To evaluate the feasibility and safety of renal denervation using an irrigated catheter. Methods Ten patients with resistant hypertension underwent the procedure. The primary endpoint was safety, as assessed by periprocedural adverse events, renal function and renal vascular abnormalities at 6 months. The secondary endpoints were changes in blood pressure levels (office and ambulatory monitoring) and in the number of antihypertensive drugs at 6 months. Results The mean age was 47.3 (± 12) years, and 90% of patients were women. In the first case, renal artery dissection occurred as a result of trauma due to the long sheath; no further cases were observed after technical adjustments, thus showing an effect of the learning curve. No cases of thrombosis/renal infarction or death were reported. Elevation of serum creatinine levels was not observed during follow-up. At 6 months, one case of significant renal artery stenosis with no clinical consequences was diagnosed. Renal denervation reduced office blood pressure levels by 14.6/6.6 mmHg, on average (p = 0.4 both for systolic and diastolic blood pressure). Blood pressure levels on ambulatory monitoring decreased by 28/17.6 mmHg (p = 0.02 and p = 0.07 for systolic and diastolic blood pressure, respectively). A mean reduction of 2.1 antihypertensive drugs was observed. Conclusion Renal denervation is feasible and safe in the treatment of resistant systemic arterial hypertension. Larger studies are required to confirm our findings.